Back to Top

m-RESIST: First European mHealth project for patients with treatment-resistant schizophrenia

29 January 2015

m-RESIST is an innovative project aimed to manage schizophrenia in patients resistant to treatment and to help their carers.
The objective is also to further develop knowledge related to the illness by studying predictive models.

Barcelona, 29 January 2015 - Today begins the m-RESIST Project (Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia), a European Project aimed to develop a therapeutic program that draws on the support of mobile devices to actively involve patients with treatment-resistant schizophrenia, to make them capable of self-managing their own illness, as well as to support their carers.

Coordinated by the Fundació TicSalut (Ministry of Health of the Government of Catalonia), the m-RESIST project is financed by European Union Horizon 2020 research and innovation framework program, and has a budget of €4 million. m-RESIST relies on the clinical leadership of the Hospital de la Santa Creu i Sant Pau (Barcelona), and the technological leadership of the iMinds Belgian research institute. A total of 12 entities from the public and private sector participate in the project, including hospitals, research centres, universities and companies from 7 European countries.

In the European Union, around 5 million people suffer from psychotic disorders, being schizophrenia one of the most widely-known . Around 30-50% patients are considered treatment-resistant and present persistent symptoms, requiring long periods of hospital care and being at greater risk of mortality and multi morbidity.

The project started on 1 January 2015, and during the 3 years of the project a model of analysis will be implemented, in order to move forward in understanding resistant schizophrenia. Besides, project activities will help to predict patient’s behaviour and to allow the establishment of a reaction alert system, as well as to draw up protocols and recommendations to give doctors support in the clinical decisions. By linking data mining tools with a high-level predictive model, m-RESIST will bring forth a new technical focus for health treatments, which will allow the behaviour patterns found in many patient data to be analysed in order to identify the risks and shortcomings of the treatments.

It is a highly innovative project, as it is the first time in Spain and Europe that a therapeutic project is developed for schizophrenic patients resistant to treatment using mHealth tools. These tools will be developed to allow patientsto play a more active role in managing their own illness, and we hope this will have a positive effect on adherence to treatment and a reduction of persistent serious symptoms, relapses and hospitalisation”, says Dr. Iluminada Corripio, the leader of the m-RESIST project at the Hospital de la Santa Creu i Sant Pau.

The m-RESIST solution will be tested in 3 pilot trials with real users in Catalonia, Israel and Hungary.

We hope that m-Resist will bring a real benefit for schizophrenic patients by extending the area of application of the personalised pharmacological and psychological treatment, not only improving the persistence of care and the participation of the carers, but also by creating a broad database to allow development in characterising the profile of the resistant schizophrenic”, says Dr. Asaf Caspi, Director of Ambulatory Psychiatric Services at the Sheba Medical Center (Israel), who leads m-RESIST project at Gertner Institute.

Participants in the project:
Fundació TicSalut (Spain), Hospital de la Santa Creu i Sant Pau (Spain), Parc Sanitari Sant Joan de Déu (Spain), The Gertner Institute for Epidemiology & Health Policy Research (Israel), Oulun Yliopisto (Finland), iMinds VZW (Belgium), IBM Global Services España SA (Spain), Athens Technology Center SA (Greece), Semmelweis Egyetem (Hungary), Agència De Qualitat I Avaluació Sanitàries De Catalunya (Spain), AB.ACUS SRL (Italy) and Institute of Communication and Computer Systems (Greece).

Further information
Contact:
Fundació TicSalut. Margarita Hospedales Salomó. +34 935034868
Hospital de la Santa Creu i Sant Pau. Iluminada Corripio Collado. +34 935537840
Athens Technology Center S.A
Anna Triantafillou. +30 210 6874 300